– CANADA, Vancouver – Aequus Pharmaceuticals Inc. (TSX-V:AQS / OTCQB:AQSZF), a specialty pharmaceutical company with a focus on developing, advancing and promoting differentiated products, announced that following the completion of its Annual General Meeting held on July 10, 2018, Damien King has joined its Board of Directors to fill the seat previously held by Dr. Fotios Plakogiannis who did not stand for re-election.

Mr. King is currently the Director of Sales with Merz Pharma Canada and sits as a founding member of their Senior Leadership Team. Over the past 9 years, Mr. King has been instrumental in transforming Merz from a single brand entity, to an integrated product portfolio organization with five divisions and multiple high performing teams.

“We welcome Damien to our Board. He is an industry veteran with a track record for operating and creating shareholder value within rapidly growing pharmaceutical companies. I have no doubt Damien will provide valuable strategic and operational guidance to Aequus’ Board and business, as we continue to grow our commercial division,” said Doug Janzen, Chairman and CEO of Aequus. “Damien’s addition to the Board marks another milestone in the company’s growth as we add Directors and advisors with strategic growth expertise in the Canadian pharmaceutical industry.”

Mr. Janzen continued, “I would like to personally thank Dr. Plakogiannis for his contributions to the Company as a founder and past director. We value Fotios’ contributions and expertise and look forward to continuing to engage with him as it relates to our transdermal programs.”

Aequus’ five incumbent directors, Doug Janzen, Anne Stevens, Chris Clark, Jason Flowerday and Rodoula Plakogiannis, were all re-elected as directors of the Company by shareholders at its annual general meeting held on July 10, 2018.

About Aequus Pharmaceuticals Inc.

Aequus Pharmaceuticals Inc. (TSX-V:AQS) (OTCQB:AQSZF) is a growing specialty pharmaceutical company focused on developing and commercializing high quality, differentiated products. Aequus has grown its pipeline to include several commercial products in ophthalmology and transplant, and a development stage pipeline in neurology and psychiatry with a goal of addressing the need for improved medication adherence through enhanced delivery systems. As a complement to its focus in neurology, our most recent addition to the development pipeline was a long-acting form of medical cannabis, where there is a high need for a consistent, predictable and pharmaceutical-grade delivery of products for patients. Aequus intends to commercialize its internal programs in Canada alongside its current portfolio of marketed established medicines and will look to form strategic partnerships that would maximize the reach of its product candidates worldwide. Aequus plans to build on its Canadian commercial platform through the launch of additional products that are either created internally or brought in through an acquisition or license; remaining focused on highly specialized therapeutic areas.

For more information : http://www.aequuspharma.ca

- DisclaimerNews, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.

Talent4Boards Team

here the original post =>

Comments are closed.